Fidelis Capital Partners LLC Makes New Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Fidelis Capital Partners LLC bought a new stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) in the 2nd quarter, HoldingsChannel reports. The firm bought 12,762 shares of the specialty pharmaceutical company’s stock, valued at approximately $71,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Los Angeles Capital Management LLC boosted its position in shares of Eagle Pharmaceuticals by 110.1% during the 1st quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock valued at $1,005,000 after acquiring an additional 100,470 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Eagle Pharmaceuticals by 378.7% in the 4th quarter. BNP Paribas Financial Markets now owns 88,685 shares of the specialty pharmaceutical company’s stock valued at $464,000 after buying an additional 70,158 shares during the period. Trexquant Investment LP grew its stake in shares of Eagle Pharmaceuticals by 88.0% in the 4th quarter. Trexquant Investment LP now owns 126,282 shares of the specialty pharmaceutical company’s stock valued at $660,000 after buying an additional 59,095 shares during the period. DGS Capital Management LLC increased its holdings in shares of Eagle Pharmaceuticals by 442.5% during the 1st quarter. DGS Capital Management LLC now owns 61,944 shares of the specialty pharmaceutical company’s stock worth $325,000 after buying an additional 50,525 shares during the last quarter. Finally, AIGH Capital Management LLC raised its position in shares of Eagle Pharmaceuticals by 2.1% during the 2nd quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock valued at $6,784,000 after buying an additional 25,000 shares during the period. 85.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Eagle Pharmaceuticals in a research report on Wednesday, September 18th. They issued a “hold” rating for the company.

Eagle Pharmaceuticals Trading Down 1.6 %

NASDAQ EGRX opened at $3.90 on Tuesday. The stock has a fifty day simple moving average of $4.66 and a 200-day simple moving average of $4.70. The stock has a market cap of $50.58 million, a PE ratio of 3.30 and a beta of 0.53. Eagle Pharmaceuticals, Inc. has a twelve month low of $3.21 and a twelve month high of $15.91.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.